Treatment Trials

9 Clinical Trials for Various Conditions

Focus your search

COMPLETED
SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells
Description

This randomized phase II trial is studying how well SGN-00101 vaccine works compared to a placebo in treating human papillomavirus and preventing cervical cancer in patients with abnormal cervical cells. Vaccines, such as SGN-00101, may make the body build an immune response to kill human papillomavirus and abnormal cervical cells and may be effective in preventing cervical cancer

COMPLETED
Activating Collaborative CIS Support Via Targeted Provider Mailing
Description

RATIONALE: Receiving a reminder letter from their doctor with questions to ask the Cancer Information Service may be more effective than a standard reminder letter in helping patients who have had an abnormal Pap test keep their follow-up colposcopy appointment. PURPOSE: This randomized clinical trial is studying a personalized letter with Cancer Information Service support to see how well it works compared with a standard reminder letter in women scheduled for colposcopy after an abnormal Pap test.

COMPLETED
Folic Acid Clinical Trial for the Prevention of Cervical Cancer
Description

RATIONALE: Supplements, such as folic acid, may stop or delay the development of cervical cancer in women infected with human papillomavirus. PURPOSE: This phase II trial is studying how well folic acid supplements work in preventing cancer in women infected with human papillomavirus.

COMPLETED
Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials
Description

RATIONALE: Diagnostic procedures, such as anal swab collection, digital rectal examination, and anal endoscopy and biopsy, may help find and diagnose anal and genital human papillomavirus infection and squamous intraepithelial lesions and help doctors plan better treatment. PURPOSE: This clinical trial is studying ways to detect anal and genital human papillomavirus infection and squamous intraepithelial lesions in HIV-positive patients enrolled in an AIDS cancer clinical trial.

COMPLETED
The Effects of MBSR in Improving Immune Response to Human Papillomavirus in Patients With Cervical Dysplasia
Description

RATIONALE: Mindfulness-based stress reduction (MBSR) may reduce patient stress and improve quality of life. It is not yet known whether mindfulness-based stress reduction is effective in improving immune response to human papillomavirus in patients with cervical dysplasia. PURPOSE: This randomized clinical trial is studying whether mindfulness-based stress reduction (MBSR) or a general diet and physical activity program has any effects on immune response to human papillomavirus in patients with cervical dysplasia.

COMPLETED
Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
Description

RATIONALE: Vaccines made from human papillomavirus may help the body build an effective immune response to kill HIV cells. PURPOSE: This phase II trial is studying the side effects and how well human papillomavirus vaccine therapy works in treating men with HIV-1 infection.

COMPLETED
Assessing Drivers and Barriers to Follow-Up Screening for Anal Cancer in Men Who Have Sex With Men
Description

This study is designed to identify barriers that prevent men who have sex with men from receiving doctor-recommended annual follow-up screenings for anal cancer. Men who are at the highest risk for developing anal cancer will be asked to complete a brief questionnaire (either via telephone or in writing). The questionnaire is designed to identify potential barriers to care-seeking behavior including, relationship status, financial constraints, highest level of education and knowledge about anal cancer and its precursors. The men who agree to participate in the study will then be organized into groups based on their history of coming in for follow-up screening visits after learning that they are at higher risk for developing anal cancer. These groups include 1) men that have come in for regular screening visits (at least once per year), 2) men who came in once and were then lost to follow-up, 3) men who came in for more than one screening visit and were then lost to follow-up, and 4) men who were previously lost to follow-up and then began coming in for screening again. By comparing the men's responses across the different groups, we hope to uncover key barriers and drivers to follow-up screenings for anal cancer. The goal of this study is to evaluate the differences in questionnaire responses across cohorts that may impact care-seeking behavior. We hypothesize that: * Patients who regularly comply with annual follow-up screening visits score higher on questions assessing knowledge of HPV and anal cancer. * Men in stable relationships are more likely to comply with annual screening visit recommendations. * Men who are educated by their primary care physicians about the importance of anal cancer screenings have higher screening rates.

Conditions
ACTIVE_NOT_RECRUITING
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients with Cervical, Vaginal and Vulvar Dysplasia and Cancer
Description

This trial studies the prevalence of anal dysplasia and anal cancer in patients with cervical, vaginal, and vulvar dysplasia and cancer. Studying samples collected from patients in the laboratory may help doctors learn more about the human papillomavirus and how often anal cancer occurs in patients with cervix, vagina, or vulvar cancer.

Conditions
Cervical AdenocarcinomaCervical Adenocarcinoma in SituCervical Intraepithelial NeoplasiaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedCervical Squamous Intraepithelial NeoplasiaEarly Invasive Cervical AdenocarcinomaEarly Invasive Cervical Squamous Cell CarcinomaHigh Grade Cervical Squamous Intraepithelial NeoplasiaHigh Grade Vaginal Intraepithelial NeoplasiaLow Grade Vaginal Intraepithelial NeoplasiaStage I Cervical Cancer AJCC V8Stage I Vaginal Cancer AJCC V8Stage I Vulvar Cancer AJCC V8Stage IA Cervical Cancer AJCC V8Stage IA Vaginal Cancer AJCC V8Stage IA Vulvar Cancer AJCC V8Stage IA1 Cervical Cancer AJCC V8Stage IA2 Cervical Cancer AJCC V8Stage IB Cervical Cancer AJCC V8Stage IB Vaginal Cancer AJCC V8Stage IB Vulvar Cancer AJCC V8Stage IB1 Cervical Cancer AJCC V8Stage IB2 Cervical Cancer AJCC V8Stage II Cervical Cancer AJCC V8Stage II Vaginal Cancer AJCC V8Stage II Vulvar Cancer AJCC V8Stage IIA Cervical Cancer AJCC V8Stage IIA Vaginal Cancer AJCC V8Stage IIA1 Cervical Cancer AJCC V8Stage IIA2 Cervical Cancer AJCC V8Stage IIB Cervical Cancer AJCC V8Stage IIB Vaginal Cancer AJCC V8Stage III Cervical Cancer AJCC V8Stage III Vaginal Cancer AJCC V8Stage III Vulvar Cancer AJCC V8Stage IIIA Cervical Cancer AJCC V8Stage IIIA Vulvar Cancer AJCC V8Stage IIIB Cervical Cancer AJCC V8Stage IIIB Vulvar Cancer AJCC V8Stage IIIC Vulvar Cancer AJCC V8Stage IV Cervical Cancer AJCC V8Stage IV Vaginal Cancer AJCC V8Stage IV Vulvar Cancer AJCC V8Stage IVA Cervical Cancer AJCC V8Stage IVA Vaginal Cancer AJCC V8Stage IVA Vulvar Cancer AJCC V8Stage IVB Cervical Cancer AJCC V8Stage IVB Vaginal Cancer AJCC V8Stage IVB Vulvar Cancer AJCC V8Vaginal AdenocarcinomaVulvar AdenocarcinomaVulvar High Grade Squamous Intraepithelial LesionVulvar Intraepithelial NeoplasiaVulvar Squamous Cell CarcinomaVulvar Squamous Intraepithelial Lesion
TERMINATED
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
Description

The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.